Given that aberrant apoptotic mechanisms are often linked to chemo-resistance [37, 38], targeting LTB4R could lead to novel intervention strategies applicable beyond CRC to other malignancies like ovarian and breast cancers. The gene discussed is LTB4R; the disease is breast cancer.